A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma

Melanoma (Skin) Clinical Trial

Official title:

A Phase I Study With a Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Metastatic Melanoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04072900
• Other study ID #: XYM001
• Status: Recruiting
• Phase: Phase 1
• Start date: April 21, 2020
• Est. completion date: September 1, 2022

Study information

• Verified date: April 2020
• Source: Xiangya Hospital of Central South University
• Contact: Xiang Chen, Doctor's
• Phone: +86-8975-3406
• Email: chenxiangck[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study assessed the safety and efficacy of individualized new antigen cancer vaccine combined with Programmed Cell Death Protein 1（PD1） inhibitor Toripalimab in the treatment of metastatic cutaneous melanoma. Melanoma is the most malignant skin neoplasm. Immunotherapy is the main treatment at present. PD1 is an immunological checkpoint and the inhibitors can reduce the immune escape of tumors, enhance T cell function and kill tumors. At present, PD1 antibody is the representative drug of immunotherapy, but the overall efficiency of its single drug treatment of acral melanoma is still low, and the combined treatment can significantly improve the efficiency. Melanoma has a high mutation load, which makes each patient have mutations specific to individual patients and tumors (changes in genetic material). These mutations lead to tumour cells producing proteins that are distinct from those of the body's own cells. These proteins used in vaccines may cause a strong immune response, which may help participants' bodies fight against any cancer cells that may lead to future recurrence of melanoma. Inhibition of PD1 can enhance the activity of T cells and form T cells with sustained killing activity. Tumor vaccines activate human Antigen Presenting Cells (APC) by injecting tumor antigens and adjuvants, and then activate T cells by APC to produce specific killing T cells. Therefore, the combination of "tumor vaccine + PD1 inhibitor" can produce effective specific killing and sustained activation of T cells, and prevent the establishment of inhibitory tumor microenvironment by tumor cells. The study will examine the safety and efficiency of the combined therapy at different time points and assess whether there is an immune response in the patient's peripheral blood and tumor tissue.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: September 1, 2022
• Est. primary completion date: September 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Patients must meet the following criteria on screening examination to be eligible to participate in the study:

2. Patient is willing and able to give written informed consent.

3. Age = 18 years, =75 years

4. Pathologically confirmed, clinically evident (by physical examination or radiographic imaging) stage IIIDN3c?IVM1a?M1b?M1c cutaneous melanoma.

5. Lesions that can be measured,and at least one lesion that can be used to evaluate the efficacy of immunotherapy;Multiple biopsies are available for lesions.

6. Patient is agreeable to allow tumor?normal tissue samples and blood samples to be submitted for genomic/complete exome/transcriptional sequencing;

7. ECOG score is 0 or 1

8. Life expectancy >6 months

9. Normal organ and bone marrow function as defined below:

Leukocytes = 3,500/mcL Absolute lymphocyte count > 800/mcL Absolute neutrophil count > 1,500/mcL Platelets > 100,000/mcL Hemoglobin > 10.0 g/dL Total serum bilirubin < 1.0 x institutional upper limit of normal AST (SGOT)/ALT (SGPT) < 2.0 x institutional upper limit of normal Serum creatinine< 1.5 x institutional upper limit of normal

10. Women of childbearing potential (WOCBP) must have a negative pregnancy test before entering the trial and within 7 days prior to start of study medication.

11. Female patients enrolled in the study, short-term have no fertility plan and must agree to use an adequate method of contraception starting with the first dose of study therapy through 90 days after the last dose of study therapy.

12. Male patients must agree to use an adequate method of contraception starting with the first dose of study therapy through 90 days after the last dose of study therapy.

13. Good compliance, able to follow research protocols and follow-up procedures.

Exclusion Criteria:

1. Patients who meet any of the following criteria will not be eligible for this study.

2. Uveal or mucosal melanoma;

3. Patients who received immunotherapy or other targeted cancer therapy within 4 weeks (including, but not limited to: IL-2, CTLA-4 blockade, PD-1/PD-L1 blockade, but exception of INF-a given as adjuvant treatment)

4. Previous bone marrow or stem cell transplant

5. History of severe allergic reactions attributed to any vaccine therapy

6. Active, known, or suspected autoimmune disease with the exception of vitiligo, type 1 diabetes, or psoriasis not requiring systemic treatment.

7. Use of a non-oncology vaccine therapy for prevention of infectious diseases (up-to) 4 weeks prior to enrollment to the study. Patients may not receive any non-oncology vaccine therapy during the period of NeoVax administration and until at least 8 weeks after the last dose of study therapy

8. In an immunosuppressive stage or immunosuppressive drugs were used systematically within 2 weeks.

9. Patients with long-term use of glucocorticoids or with experimental anti-tumor drugs

10. Active bacterial or fungal infections identified clinically (>= level 2 of NCI-CTC edition 3);

11. Known chronic infections with HIV, hepatitis B or C

12. Known active or latent tuberculosis infection

13. A history of idiopathic pulmonary fibrosis and organized pneumonia, or active pneumonia on chest computed tomography.

14. Complicated with other tumors, except for cervical cancer in situ and basal cell carcinoma five years ago.

15. Severe coronary or cerebrovascular disease, or other diseases that the investigators considered should to be exclusion;

16. Drug abuse, Clinical, psychological or social factor result in affecting informed consent or research implementation.

Related Conditions & MeSH terms

• Melanoma
• Melanoma (Skin)

Intervention

Drug:
• Peptide
4 x 3 mg all the peptides given on days 84,87,91,98,105,133,and 161
• Anti-PD-1
3mg/kg, ivgtt, Q2w
• rhGM-CSF
3µg/kg given on Days 81,82,83,95,96,97,102,103,104,130,131,132,158,159,and 160
• Imiquimod 5% Topical Cream
topical application on the injection site 6 hours before each NeoAntigen peptides injection

Locations

Country	Name	City	State
China	Xiangya Hospital, Central South University	Changsha	Hunan

Sponsors (1)

Lead Sponsor	Collaborator
Xiangya Hospital of Central South University

Country where clinical trial is conducted

China, 

References & Publications (2)

Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, — View Citation

Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, Omokoko T, Vormehr M, Albrecht C, Paruzynski A, Kuhn AN, Buck J, Heesch S, Schreeb KH, Müller F, Ortseifer I, Vogler I, Godehardt E, Attig S, Ra — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants experiencing adverse events	Number of participants experiencing clinical and laboratory adverse events (AE)	up to a maximum of 252 days
Primary	Number of Patients with Complete Remission Rate	Number of Patients with Complete Remission Rate(CRR)	up to a maximum of 252 days
Primary	Number of Patients with Progressive Disease	Number of Patients with Progressive Disease(PD)	up to a maximum of 252 days
Primary	Number of Patients with Partial Response	Number of Patients with Partial Response(PR)	up to a maximum of 252 days
Secondary	Monitoring of cellular immune response	the immune response of serum and tumor tissue	up to a maximum of 252 days